Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 7/2006

01-07-2006 | Editorial

Desmopressin

Safety Considerations in Patients with Chronic Renal Disease

Authors: Dr Domenic A. Sica, Todd W.B. Gehr

Published in: Drug Safety | Issue 7/2006

Login to get access

Excerpt

Desmopressin is a synthetic analogue of mammalian 8-arginine vasopressin (antidiuretic hormone), which is a hormone crucial to renal water conservation. Desmopressin was first developed as antidiuretic-replacement therapy in the management of central diabetes insipidus and it thereafter came into use for the management of the transitory polyuria and polydipsia following head trauma and/or surgery in the pituitary region.[1] Desmopressin has since gained an indication for use in primary nocturnal enuresis and has been applied to the management of night-time urinary incontinence.[2,3] Desmopressin is also a well tolerated and conveniently administered haemostatic agent that can be used in a number of clinical conditions marked by a bleeding diathesis.[4,5] It causes the release of coagulation factor VIII, von Willebrand factor and tissue-type plasminogen activator, among other haemostatic properties.[6,7] …
Literature
1.
Kim RJ, Malattia C, Allen M, et al. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. Pediatr Endocrinol Rev 2004; 2Suppl 1: 115–23PubMed
2.
Wolfish NM, Barkin J, Gorodzinsky F, et al. The Canadian Enuresis Study and Evaluation: short- and long-term safety and efficacy of an oral desmopressin preparation. Scand J Urol Nephrol 2003 37: 22–7PubMedCrossRef
3.
Johnson II TM, Miller M, Tang T, et al. Oral ddAVP for nighttime urinary incontinence in characterized nursing home residents: a pilot study. J Am Med Dir Assoc 2006 7: 6–11PubMedCrossRef
4.
Manucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-Darginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983 308: 8–12CrossRef
5.
Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s diseases. Lancet 1977 I: 869–72CrossRef
6.
Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682–9PubMedCrossRef
7.
8.
9.
Escolar G, Diaz-Ricart M, Cases A. Uremic platelet dysfunction: past and present. Curr Hematol Rep 2005; 4: 359–67PubMed
10.
Sohal AS, Gangji AS, Crowther MA, et al. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 2005, [epub ahead of print]
11.
Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87–93
12.
Canavese C, Salomone M, Pacitti A, et al. Reduced response of uraemic bleeding time to repeated doses of desmopressin. Lancet 1985 I: 867–8CrossRef
13.
Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol 2004 60: 397–402PubMedCrossRef
14.
Fjellestad-Paulsen A, Hoglund P, Lundin S, et al. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf) 1993 38: 177–82CrossRef
15.
Ruzicka H, Bjorkman S, Lethagen S, et al. Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. Pharmacol Toxicol 2003 92: 137–42PubMedCrossRef
16.
Agerso H, Seiding Larsen L, Riis A, et al. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol 2004 58: 352–8PubMedCrossRef
17.
Dunn AL, Powers JR, Ribeiro MJ, et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000 6: 11–4PubMedCrossRef
18.
Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006; 25105–9PubMedCrossRef
19.
Callreus T, Ekman E, Andersen M. Hyponatremia in elderly patients treated with desmopressin for nocturia: a review of case series. Eur J Clin Pharmacol 2005; 61281–4PubMedCrossRef
20.
Shepherd LL, Hutchinson RJ, Worden EK, et al. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989 114: 470–2PubMedCrossRef
21.
Package Insert. Desmopressin acetate (DDAVP®). Aventis Pharmaceuticals Inc. Bridgewater (NJ)
22.
Package Insert. Metformin (Glucophage®). Bristol-Myers Squibb Inc. Princeton (NJ)
23.
Package Insert. Dofetilide (Tikosyn®). Pfizer Pharmaceuticals Inc. New York (NY)
24.
Package Insert. Sotalol hydrochloride (Betapace®). Berlex Laboratories Inc. Wayne (NJ)
25.
Ulusoy S, Ovali E, Aydin F, et al. Hemostatic and fibrinolytic response to nasal desmopressin in hemodialysis patients. Med Princ Pract 2004 13: 340–5PubMedCrossRef
Metadata
Title
Desmopressin
Safety Considerations in Patients with Chronic Renal Disease
Authors
Dr Domenic A. Sica
Todd W.B. Gehr
Publication date
01-07-2006
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 7/2006
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200629070-00001

Other articles of this Issue 7/2006

Drug Safety 7/2006 Go to the issue

Correspondence

A Survey of the Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting by Clinicians in Eastern India

Original Research Article

Increase in Nonfatal Digestive Perforations and Haemorrhages Following Introduction of Selective NSAIDs

Original Research Article

Temporal Relationship between Use of NSAIDs, Including Selective COX-2 Inhibitors, and Cardiovascular Risk

Review Article

Heart Failure Induced by Non-Cardiac Drugs

Original Research Article

Safety of Inhalation of a 50% Nitrous Oxide/Oxygen Premix

Current Opinion

Use of the Dose, Time, Susceptibility (DoTS) Classification Scheme for Adverse Drug Reactions in Pharmacovigilance Planning